-
(2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine; 2-hydroxypropane-1,2,3-tricarboxylic acid
-
ChemBase ID:
51111
-
Molecular Formular:
C32H37NO8
-
Molecular Mass:
563.63808
-
Monoisotopic Mass:
563.25191715
-
SMILES and InChIs
SMILES:
C(CC(=O)O)(CC(=O)O)(C(=O)O)O.C(=C(\c1ccccc1)/CC)(\c1ccc(cc1)OCCN(C)C)/c1ccccc1
Canonical SMILES:
OC(=O)CC(C(=O)O)(CC(=O)O)O.CC/C(=C(\c1ccccc1)/c1ccc(cc1)OCCN(C)C)/c1ccccc1
InChI:
InChI=1S/C26H29NO.C6H8O7/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,4,19-20H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;
InChIKey:
FQZYTYWMLGAPFJ-OQKDUQJOSA-N
-
Cite this record
CBID:51111 http://www.chembase.cn/molecule-51111.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
(2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine; 2-hydroxypropane-1,2,3-tricarboxylic acid
|
|
|
IUPAC Traditional name
|
|
Synonyms
|
{2-[4-(1,2-Diphenyl-1-buten-1-yl)phenoxy]ethyl}dim ethylamine 2-hydroxy-1,2,3-propanetricarboxylate (
|
Nolvadex
|
Istubal
|
Valodex
|
Tamoxifen Citrate
|
Tamoxifen citrate salt
|
他莫昔芬 柠檬酸盐
|
(Z)-1-(对二甲基氨基乙氧基苯基)-1,2-二苯基-1-丁烯
|
|
|
CAS Number
|
|
EC Number
|
|
MDL Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
H Acceptors
|
2
|
H Donor
|
0
|
LogD (pH = 5.5)
|
3.2851102
|
LogD (pH = 7.4)
|
4.971639
|
Log P
|
6.351222
|
Molar Refractivity
|
128.4308 cm3
|
Polarizability
|
46.4946 Å3
|
Polar Surface Area
|
12.47 Å2
|
Rotatable Bonds
|
13
|
Lipinski's Rule of Five
|
false
|
PROPERTIES
PROPERTIES
Safety Information
Pharmacology Properties
Product Information
Bioassay(PubChem)
Storage Condition
|
-20°C
|
Show
data source
|
|
Storage Warning
|
IRRITANT
|
Show
data source
|
|
RTECS
|
KH2387000
|
Show
data source
|
|
European Hazard Symbols
|
Toxic (T)
|
Show
data source
|
|
MSDS Link
|
|
German water hazard class
|
3
|
Show
data source
|
|
Risk Statements
|
45-60-61-22-64
|
Show
data source
|
|
Safety Statements
|
36/37/39-45
|
Show
data source
|
|
TSCA Listed
|
false
|
Show
data source
|
|
GHS Pictograms
|
|
Show
data source
|
|
Show
data source
|
|
GHS Signal Word
|
Danger
|
Show
data source
|
|
GHS Hazard statements
|
H302-H350-H360
|
Show
data source
|
|
GHS Precautionary statements
|
P201-P308 + P313
|
Show
data source
|
|
Personal Protective Equipment
|
Eyeshields, full-face particle respirator type N100 (US), Gloves, respirator cartridge type N100 (US), type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges
|
Show
data source
|
|
Storage Temperature
|
2-8°C
|
Show
data source
|
|
Gene Information
|
human ... PRKCA(5578), PRKCB(5579), PRKCD(5580), PRKCE(5581), PRKCG(5582), PRKCH(5583), PRKCI(5584)
|
Show
data source
|
|
Purity
|
≥99%
|
Show
data source
|
|
Salt Data
|
Citrate
|
Show
data source
|
|
DETAILS
DETAILS
Selleck Chemicals
Sigma Aldrich
Selleck Chemicals -
S1972
|
Research Area: Endocrinology Biological Activity: Tamoxifen Citrate (Nolvadex) is an estrogen receptor antagonist with an IC50 of 31 μM for the MCF-7 cells. In some tissues such as the endometrium, it behaves as an agonist, hence tamoxifen may be characterized as a mixed agonist/antagonist. It has been the standard endocrine (anti-estrogen) therapy for hormone-positive early breast cancer in pre-menopausal women, although aromatase inhibitors have been proposed. [1][2]References on Tamoxifen Citrate (Nolvadex)[] Journal of Steroid Biochemistry & Molecular Biology, 2003, 84 :255–257 |
Sigma Aldrich -
T9262
|
Biochem/physiol Actions Protein kinase C inhibitor. Induces apoptosis in human malignant glioma cell lines. Tamoxifen and its metabolite 4-hydroxytamoxifen are selective estrogen response modifiers (SERMs) that act as estrogen antagonists in mammary gland. Blocks estradiol-stimulated VEGF production in breast tumor cells. |
PATENTS
PATENTS
PubChem Patent
Google Patent